Related Experiment Videos
High dosage haloperidol in chronic schizophrenia
Insights
High-dose haloperidol significantly improved chronic schizophrenic patients. Some patients maintained benefits on lower doses, with side effects resolving upon dose reduction or discontinuation.
Area of Science:
- Psychiatry
- Clinical Pharmacology
- Neuroscience
Background:
- Chronic 'drug-resistant' schizophrenia presents significant treatment challenges.
- Long-term inpatient care settings require effective management strategies for persistent symptoms.
Purpose of the Study:
- To evaluate the efficacy and safety of high-dose haloperidol in chronic, drug-resistant male schizophrenic inpatients.
- To assess the potential for dose reduction in maintaining treatment gains and managing side effects.
Main Methods:
- A double-blind, chlorpromazine-controlled trial was conducted over three months.
- High-dose haloperidol (100 mg daily) was administered to male chronic schizophrenic inpatients.
- A three-month follow-up assessed maintenance of improvement and side effect profiles.
Main Results:
- High-dose haloperidol demonstrated significant improvement in the mental state of participants.
- Serious extrapyramidal side effects were not observed at high doses.
- A majority of patients experienced behavioral deterioration (e.g., drowsiness) and elevated serum alkaline phosphatase levels.
- These side effects resolved upon dose reduction or drug discontinuation during follow-up.
Conclusions:
- High-dose haloperidol can be effective for improving the mental state in chronic, drug-resistant schizophrenia.
- Lower doses may maintain improvements, and side effects are manageable through dose adjustment or cessation.
- Careful monitoring for behavioral changes and biochemical markers is warranted with high-dose haloperidol therapy.
Abstract:
In a double blind chlorpromazine-controlled trial, high dosage haloperidol (100 mg daily) given for three months, appreciably improved the mental state of male chronic 'drug resistant' schizophrenic inpatients in the rehabilitation/long-stay unit of one psychiatric hospital. The results of a three-month follow-up suggested that the improvement could be maintained in some patients on lower doses of the drug. Serious extrapyramidal side effects were not seen at high doses. However, the majority of patients on haloperidol showed a deterioration in ward behaviour, possibly related to drowsiness, and developed raised serum alkaline phosphatase levels. These side effects disappeared in the follow-up period when either the drug was discontinued or the dose of haloperidol reduced.